2 January 2020 - Innate Pharma today announced that the EMA has accepted the marketing authorisation application for Lumoxiti (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukaemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

The EMA filing is based on the final analysis of the pivotal Phase III trial of Lumoxiti, presented at ASH 2019.

Read Innate Pharma press release